Osmotic diuretics – Mannitol MCQs With Answer

Introduction: Osmotic diuretics, especially Mannitol, are essential topics for B.Pharm students studying clinical pharmacology and therapeutics. Mannitol is a low‑molecular‑weight sugar alcohol that produces osmotic diuresis by increasing plasma and tubular fluid osmolarity, reducing intracranial and intraocular pressure, and promoting renal perfusion. Key points include mechanism of action, site of action (proximal tubule and thin descending limb), pharmacokinetics (not metabolized, renally excreted), common formulations (10–25%), indications, contraindications, adverse effects (pulmonary edema, electrolyte imbalance), dosing and monitoring (serum osmolality). This focused review will prepare you to apply concepts clinically. Now let’s test your knowledge with 30 MCQs on this topic.

Q1. What is the primary mechanism of action of Mannitol as an osmotic diuretic?

  • Inhibition of Na+/K+/2Cl− cotransporter in thick ascending limb
  • Blocking aldosterone receptors in collecting duct
  • Increasing tubular fluid osmolarity to inhibit water reabsorption
  • Inhibition of carbonic anhydrase in proximal tubule

Correct Answer: Increasing tubular fluid osmolarity to inhibit water reabsorption

Q2. Which nephron segments are primarily affected by osmotic diuretics like Mannitol?

  • Thick ascending limb only
  • Collecting duct only
  • Proximal tubule and descending limb of loop of Henle
  • Distal convoluted tubule only

Correct Answer: Proximal tubule and descending limb of loop of Henle

Q3. Mannitol reduces intracranial pressure effectively when which condition is present?

  • Blood–brain barrier is intact
  • Large intracerebral hemorrhage with disrupted barrier
  • Severe hypotension
  • When renal function is absent

Correct Answer: Blood–brain barrier is intact

Q4. Which of the following is a common indication for intravenous Mannitol?

  • Chronic hypertension management
  • Acute reduction of raised intracranial pressure
  • Maintenance fluid therapy in surgery
  • Long‑term edema control in heart failure

Correct Answer: Acute reduction of raised intracranial pressure

Q5. Mannitol is eliminated from the body primarily by which route?

  • Hepatic metabolism to sorbitol
  • Renal excretion unchanged
  • Metabolism by intestinal flora
  • Pulmonary exhalation as CO2

Correct Answer: Renal excretion unchanged

Q6. Which lab parameter should be monitored closely during Mannitol therapy to avoid toxicity?

  • Serum bicarbonate only
  • Serum osmolality and electrolytes
  • Liver function tests exclusively
  • Platelet count only

Correct Answer: Serum osmolality and electrolytes

Q7. A commonly recommended upper limit for serum osmolality during Mannitol treatment is:

  • 200 mOsm/kg
  • 320 mOsm/kg
  • 420 mOsm/kg
  • 500 mOsm/kg

Correct Answer: 320 mOsm/kg

Q8. Which adverse effect is most likely with Mannitol use in a patient with poor cardiac function?

  • Hypoglycemia
  • Pulmonary edema due to ECF expansion
  • Severe constipation
  • Agranulocytosis

Correct Answer: Pulmonary edema due to ECF expansion

Q9. Mannitol is contraindicated in which of the following conditions?

  • Oliguria with adequate perfusion
  • Anuria or severe renal failure
  • Acute glaucoma with intact BBB
  • Preventive therapy for contrast nephropathy with good urine output

Correct Answer: Anuria or severe renal failure

Q10. The typical concentration of Mannitol commonly used for IV bolus to reduce intracranial pressure is:

  • 0.9% solution
  • 5% solution
  • 20% solution
  • 50% solution

Correct Answer: 20% solution

Q11. Which property of Mannitol explains its inability to cross an intact blood–brain barrier rapidly?

  • High lipid solubility
  • Low molecular weight
  • Poor lipid permeability and polar nature
  • Strong protein binding

Correct Answer: Poor lipid permeability and polar nature

Q12. Mannitol lowers intraocular pressure primarily by:

  • Blocking aqueous humor production at ciliary body
  • Increasing trabecular outflow only
  • Creating an osmotic gradient drawing water from vitreous
  • Stimulating pupil constriction to open drainage angle

Correct Answer: Creating an osmotic gradient drawing water from vitreous

Q13. Which statement about Mannitol pharmacokinetics is correct?

  • It is extensively metabolized by the liver.
  • It is rapidly absorbed orally and undergoes first‑pass metabolism.
  • It is not metabolized and is excreted unchanged by the kidney.
  • It is converted to urea in the kidney.

Correct Answer: It is not metabolized and is excreted unchanged by the kidney.

Q14. The initial effect of Mannitol on extracellular fluid volume is:

  • Marked chronic contraction of ECF only after several days
  • Transient expansion of ECF due to intravascular fluid shift
  • Permanent increase in intracellular fluid volume
  • No change in fluid compartments

Correct Answer: Transient expansion of ECF due to intravascular fluid shift

Q15. When Mannitol is given to prevent acute renal failure after toxin exposure, the mechanism is primarily:

  • Direct detoxification of the toxin
  • Increasing renal blood flow and urine flow to flush tubules
  • Blocking tubular secretion of the toxin
  • Stimulating hepatic elimination

Correct Answer: Increasing renal blood flow and urine flow to flush tubules

Q16. Which monitoring parameter indicates effective osmotic diuresis after Mannitol administration?

  • Urine osmolality increases above plasma osmolality
  • Urine output increases and urine osmolality decreases
  • Serum potassium rises above normal immediately
  • Serum glucose falls below fasting level

Correct Answer: Urine output increases and urine osmolality decreases

Q17. Mannitol crystals may form if stored at low temperature. What is the recommended precaution before administration?

  • Freeze and thaw the solution rapidly
  • Warm the solution and inspect for crystals; use a filter if needed
  • Dilute the solution 1:10 with ethanol
  • Shake vigorously to dissolve crystals

Correct Answer: Warm the solution and inspect for crystals; use a filter if needed

Q18. Which electrolyte disturbance can occur with prolonged Mannitol‑induced diuresis?

  • Hyperkalemia only
  • Hypokalemia and hyponatremia or hypernatremia depending on net water loss
  • Isolated hypercalcemia
  • No change in electrolytes

Correct Answer: Hypokalemia and hyponatremia or hypernatremia depending on net water loss

Q19. A contraindication specific to use of Mannitol in brain injury is:

  • Presence of intact skull
  • Patients with established pulmonary embolism
  • Severe dehydration with circulatory collapse
  • Intracranial hemorrhage with destroyed blood–brain barrier causing rebound edema

Correct Answer: Intracranial hemorrhage with destroyed blood–brain barrier causing rebound edema

Q20. Typical IV bolus dosing range of Mannitol for acute elevated intracranial pressure is approximately:

  • 0.01–0.05 g/kg
  • 0.25–1 g/kg
  • 5–10 g/kg
  • 10–20 mg/kg

Correct Answer: 0.25–1 g/kg

Q21. Mannitol’s effect on renal hemodynamics includes which immediate action?

  • Decreasing renal blood flow markedly
  • Increasing renal blood flow and glomerular filtration transiently
  • Vasoconstriction of afferent arteriole only
  • Permanent damage to glomeruli

Correct Answer: Increasing renal blood flow and glomerular filtration transiently

Q22. Which of the following best describes Mannitol’s chemical classification?

  • A loop diuretic sulfonamide
  • A carbonic anhydrase inhibitor derivative
  • A sugar alcohol (polyol) osmotic agent
  • A thiazide‑type benzothiadiazine

Correct Answer: A sugar alcohol (polyol) osmotic agent

Q23. In patients at risk for acute tubular necrosis, Mannitol may be used for renal protection because it:

  • Causes intracellular swelling in tubular cells
  • Precipitates toxins in tubular lumen
  • Prevents tubular obstruction by maintaining urine flow
  • Inhibits cytochrome P450 enzymes

Correct Answer: Prevents tubular obstruction by maintaining urine flow

Q24. Which of the following statements about Mannitol and the blood–brain barrier is true?

  • Mannitol freely crosses an intact BBB and accumulates in brain parenchyma
  • Mannitol cannot enter the cerebrospinal fluid even with high doses
  • Mannitol does not cross an intact BBB, creating an osmotic gradient to draw water out
  • Mannitol is actively transported across the BBB by GLUT transporters

Correct Answer: Mannitol does not cross an intact BBB, creating an osmotic gradient to draw water out

Q25. Which of the following is a potential interaction concern when using Mannitol?

  • Concomitant lithium therapy leading to lithium retention
  • Enhanced renal excretion of drugs eliminated by glomerular filtration
  • Inactivation of aminoglycosides in plasma
  • Marked increase in warfarin anticoagulant effect

Correct Answer: Enhanced renal excretion of drugs eliminated by glomerular filtration

Q26. For safe infusion, Mannitol should ideally be administered via:

  • Oral route mixed with saline
  • Slow IV infusion into a large vein with monitoring and filter if needed
  • Subcutaneous bolus
  • Intraosseous only

Correct Answer: Slow IV infusion into a large vein with monitoring and filter if needed

Q27. Which physicochemical property of Mannitol is most relevant to its diuretic action?

  • High degree of ionization at physiological pH
  • Low water solubility
  • High osmotic activity per unit mass
  • Strong protein binding in plasma

Correct Answer: High osmotic activity per unit mass

Q28. In traumatic brain injury with disrupted BBB, Mannitol may be ineffective or harmful because:

  • It increases cerebrospinal fluid production
  • Mannitol can cross into brain tissue and cause rebound intracranial hypertension
  • It causes permanent vasodilation of cerebral vessels
  • It converts into glucose in brain tissue

Correct Answer: Mannitol can cross into brain tissue and cause rebound intracranial hypertension

Q29. Which of the following is true regarding Mannitol dosing in renal impairment?

  • No dose adjustment is necessary in all renal failure stages
  • Mannitol is contraindicated in anuria and should be used cautiously with impaired renal function
  • Dose should be doubled in renal impairment
  • Mannitol is cleared by the liver so renal impairment has no effect

Correct Answer: Mannitol is contraindicated in anuria and should be used cautiously with impaired renal function

Q30. Which monitoring sign would most quickly indicate developing pulmonary congestion during Mannitol therapy?

  • Rising serum creatinine only
  • Sudden increase in respiratory rate and crackles on lung auscultation
  • Decreased urine output without respiratory changes
  • Improved level of consciousness only

Correct Answer: Sudden increase in respiratory rate and crackles on lung auscultation

Leave a Comment